RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced that, following the licensing agreement signed with Vor Biopharma Inc. (“Vor Bio“) on June 25, 2025 for telitacicept, the two parties have signed an amendment to include RC298, a novel drug candidate independently developed by RemeGen with proprietary intellectual property, within the scope of the collaboration. Vor Bio will obtain exclusive rights for the development and commercialization of RC298 outside Greater China.
Deal Milestone
| Item | Detail |
|---|---|
| Parties | RemeGen Co., Ltd. (licensor) and Vor Biopharma Inc. (licensee) |
| Action | Amendment to the 25 Jun 2025 telitacicept licensing agreement |
| Asset Added | RC298 – next‑generation long‑acting BAFF/APRIL dual‑target inhibitor |
| Rights Granted | Exclusive development and commercialization rights outside Greater China |
| Announcement Date | 12 Nov 2026 |
Financial Terms
| Component | Value |
|---|---|
| Upfront Payment | ≈ USD 56 million total – USD 10 million cash + warrants valued ≈ USD 46 million |
| Warrant Structure | Subscription for 2.3 million Vor Bio common shares at USD 0.0001 per share (valued at Vor Bio’s 11 Nov 2026 closing price) |
| Development Milestones | Up to USD 300 million |
| Near‑Term Milestone | USD 20 million upon achievement of early clinical development and technology transfer milestones |
| Sales Milestones & Royalties | Existing licensing agreement mechanisms continue to apply, calculated on the aggregate sales of all licensed products |
The equity‑linked component of the upfront payment aligns RemeGen’s near‑term economics with Vor Bio’s share performance, while the aggregate‑sales royalty base across telitacicept and RC298 deepens RemeGen’s participation in the combined franchise.
Drug Profile – RC298
- Molecule: A next‑generation long‑acting dual‑target inhibitor of B‑cell activating factor (BAFF, also known as B‑lymphocyte stimulator, BLyS) and a proliferation‑inducing ligand (APRIL), independently developed by RemeGen with proprietary intellectual property.
- Mechanism of Action: Simultaneously inhibits the two key BAFF and APRIL pathways, blocking the survival and differentiation of pathogenic B cells and plasma cells to exert autoimmune regulatory effects.
- Preclinical Profile: Demonstrated potent inhibitory activity against both BAFF and APRIL and significantly prolonged systemic drug exposure.
- Differentiation Potential: The extended exposure profile shows potential for a differentiated, best‑in‑class efficacy and dosing regimen – a key competitive lever in chronic autoimmune indications.
- Platform Lineage: RC298 extends RemeGen’s BAFF/APRIL franchise alongside telitacicept, the dual‑target fusion protein licensed to Vor Bio in 2025.
Market Impact & Outlook
- Pipeline Monetization: The amendment converts RemeGen’s proprietary RC298 asset into immediate non‑dilutive value – USD 56 million upfront plus a near‑term USD 20 million technology‑transfer milestone – without relinquishing Greater China rights.
- Strategic Partnership Depth: Vor Bio’s decision to expand the telitacicept deal within roughly 17 months signals confidence in RemeGen’s autoimmune pipeline and positions Vor Bio as the ex‑China commercializer for a two‑asset BAFF/APRIL portfolio.
- Autoimmunity Target Validation: Dual BAFF/APRIL inhibition is an established strategy in autoimmune disease; RC298’s long‑acting profile targets less frequent dosing – a potential adherence and tolerability advantage over existing biologics.
- Milestone Runway: Up to USD 300 million in development milestones plus aggregate‑sales royalties provide RemeGen with long‑dated optionality on RC298’s clinical success.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the amended licensing agreement between RemeGen and Vor Bio, including the development, regulatory progression, and commercialization of RC298 and telitacicept, milestone achievement, and warrant valuation. Actual results may differ materially due to risks including preclinical and clinical outcomes, technology‑transfer execution, regulatory decisions, equity‑market fluctuations, and competitive dynamics in autoimmune therapies.-Fineline Info & Tech
